Based on the Harrow Health Inc stock forecast from 3 analysts, the average analyst target price for Harrow Health Inc is USD 52.10 over the next 12 months. Harrow Health Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Harrow Health Inc is Slightly Bearish, which is based on 4 positive signals and 7 negative signals. At the last closing, Harrow Health Inc’s stock price was USD 42.90. Harrow Health Inc’s stock price has changed by +9.97% over the past week, -19.12% over the past month and +357.36% over the last year.
No recent analyst target price found for Harrow Health Inc
No recent average analyst rating found for Harrow Health Inc
Company Overview Harrow Health Inc
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; MAXIDEX and FLAREX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe and the eye; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and NATACYN, a sterile, antifungal drug for the treatment of fungal blepharitis, conjunctivitis, and keratitis. In addition, it offers TOBRADEX ST, a tobramycin and dexamethasone ophthalmic suspension; VERKAZIA cyclosporine ophthalmic emulsion; NEVANAC, a non-steroidal, anti-inflammatory eye drop; and FRESHKOTE preservative free (PF) is a lubricant eye drop. The company was formerly known as Harrow Health, Inc. and changed its name to Harrow, Inc. in September 2023. Harrow, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee. Read Less
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochlo...Read More
Frequently Asked Questions About Harrow Health Inc (HROW) Stock
Based on ratings from 3 analysts Harrow Health Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 10 buy, sell and hold ratings.
Unfortunately we do not have enough data on HROW's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for HROW is USD 52.10 over the next 12 months. The maximum analyst target price is USD 73 while the minimum anlayst target price is USD 25.
HROW stock's Price/Earning ratio is 40.52.
Our analysis grades HROW stock's Price / Earning ratio at F. This means that HROW stock's Price/Earning ratio is above 56.00000000000001% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSD exchange.
Based on this HROW may be a overvalued for its sector.
The last closing price of HROW's stock was USD 42.90.
The most recent market capitalization for HROW is USD 1.86B.
Based on targets from 3 analysts, the average taret price for HROW is projected at USD 52.10 over the next 12 months.
This means that HROW's stock price may go up by +21.45% over the next 12 months.
We can't find any ETFs which contains Harrow Health Inc's stock.
As per our most recent records Harrow Health Inc has 315 Employees.
Harrow Health Inc's registered address is 102 Woodmont Boulevard, Nashville, TN, United States, 37205.
You can get more information about it from Harrow Health Inc's website at https://www.harrow.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Harrow Health Inc (HROW) Stock
Based on ratings from 3 analysts Harrow Health Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 10 buy, sell and hold ratings.
Unfortunately we do not have enough data on HROW's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for HROW is USD 52.10 over the next 12 months. The maximum analyst target price is USD 73 while the minimum anlayst target price is USD 25.
HROW stock's Price/Earning ratio is 40.52.
Our analysis grades HROW stock's Price / Earning ratio at F. This means that HROW stock's Price/Earning ratio is above 56.00000000000001% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSD exchange.
Based on this HROW may be a overvalued for its sector.
The last closing price of HROW's stock was USD 42.90.
The most recent market capitalization for HROW is USD 1.86B.
Based on targets from 3 analysts, the average taret price for HROW is projected at USD 52.10 over the next 12 months.
This means that HROW's stock price may go up by +21.45% over the next 12 months.
We can't find any ETFs which contains Harrow Health Inc's stock.
As per our most recent records Harrow Health Inc has 315 Employees.
Harrow Health Inc's registered address is 102 Woodmont Boulevard, Nashville, TN, United States, 37205.
You can get more information about it from Harrow Health Inc's website at https://www.harrow.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for HROW !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
